TWi Biotechnology（6610）株式概要臨床段階のバイオ医薬品会社であるTWi Biotechnology, Inc.は、台湾で自然免疫関連疾患の治療薬を開発・販売している。 詳細6610 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 過去5年間で収益は年間35%減少しました。 収益が 100 万ドル未満 ( NT$0 )キャッシュランウェイが1年未満である すべてのリスクチェックを見る6610 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW469,747 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA469,747 investors already sharing narrativesYour Fair ValueNT$Current PriceNT$27.20該当なし内在価値ディスカウントEst. Revenue$PastFuture-299m66m2016201920222025202620282031Revenue NT$0Earnings NT$0AdvancedSet Fair ValueView all narrativesTWi Biotechnology, Inc. 競合他社Medigen BiotechnologySymbol: TPEX:3176Market cap: NT$5.1bSteminent BiotherapeuticsSymbol: TPEX:7729Market cap: NT$6.1bMycenax BiotechSymbol: TPEX:4726Market cap: NT$5.1bTaiGen Biopharmaceuticals HoldingsSymbol: TPEX:4157Market cap: NT$6.4b価格と性能株価の高値、安値、推移の概要TWi Biotechnology過去の株価現在の株価NT$27.2052週高値NT$40.8552週安値NT$12.85ベータ0.991ヶ月の変化0.55%3ヶ月変化-4.56%1年変化23.64%3年間の変化72.15%5年間の変化48.63%IPOからの変化-59.90%最新ニュースNew Risk • Jun 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 132% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$293m free cash flow). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (132% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).お知らせ • Mar 23TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026, at 09:00 Taipei Standard Time. Location: no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$2.27b market cap, or US$72.4m).New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$1.50b (US$48.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$1.50b market cap, or US$48.2m).New Risk • Sep 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$156m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$156m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$928.9m market cap, or US$31.0m).最新情報をもっと見るRecent updatesNew Risk • Jun 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 132% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$293m free cash flow). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (132% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).お知らせ • Mar 23TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026, at 09:00 Taipei Standard Time. Location: no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$2.27b market cap, or US$72.4m).New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$1.50b (US$48.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$1.50b market cap, or US$48.2m).New Risk • Sep 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$156m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$156m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$928.9m market cap, or US$31.0m).New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$838.6m market cap, or US$25.4m).お知らせ • Mar 20TWi Biotechnology, Inc., Annual General Meeting, Jun 06, 2025TWi Biotechnology, Inc., Annual General Meeting, Jun 06, 2025, at 09:00 Taipei Standard Time. Location: no,399, jui kuang rd., neihu district, taipei city TaiwanNew Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$190m free cash flow). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.16b market cap, or US$35.4m).New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$190m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$190m free cash flow). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.22b market cap, or US$37.7m).お知らせ • Mar 29TWi Biotechnology, Inc., Annual General Meeting, Jun 26, 2024TWi Biotechnology, Inc., Annual General Meeting, Jun 26, 2024.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$39.0m).New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.22b market cap, or US$39.0m).New Risk • Oct 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.54b market cap, or US$47.4m).お知らせ • Jun 03TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)TWi Biotechnology, Inc. announced that it is currently seeking participants for a Phase 1 clinical trial of a topical gel called tofacitinib for the treatment of granuloma annulare (GA). The TWiB team and collaborating physicians invite eligible individuals to participate in this study at Yale University Hospital.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • May 02Full year 2021 earnings released: NT$0.23 loss per share (vs NT$1.51 loss in FY 2020)Full year 2021 results: NT$0.23 loss per share (up from NT$1.51 loss in FY 2020). Revenue: NT$66.4m (up NT$65.2m from FY 2020). Net loss: NT$15.3m (loss narrowed 85% from FY 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 20TWi Biotechnology, Inc., Annual General Meeting, Jun 07, 2021TWi Biotechnology, Inc., Annual General Meeting, Jun 07, 2021.Is New 90 Day High Low • Mar 11New 90-day high: NT$19.00The company is up 23% from its price of NT$15.50 on 11 December 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.お知らせ • Jan 08Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases. The prevalence of EB in the United States is about 10.65 per million, equivalent to an estimated 15,000 patients in China. Hereditary epidermolysis bullosa (EB) is a group of rare hereditary skin diseases. Due to genetic mutations, the skin becomes very fragile, just like the wings of a butterfly. A slight collision or friction produces blisters or bloody vesicles, which may then cause trauma and ulceration. Other mucosal tissues of the body may also be affected. There is no effective treatment for EB worldwide. EB is listed in the first national list of 121 rare diseases in China. Based on clinical studies conducted, AC-203 alleviates EB symptoms, reducing blister formation and accelerating wound healing, while also demonstrating a good safety profile. AC-203 has been granted Orphan Drug Designation and rare pediatric drug status by FDA.分析記事 • Dec 29We're Hopeful That TWi Biotechnology (GTSM:6610) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is New 90 Day High Low • Nov 27New 90-day high: NT$17.15The company is up 5.0% from its price of NT$16.40 on 28 August 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period.Is New 90 Day High Low • Oct 13New 90-day low: NT$13.85The company is down 41% from its price of NT$23.40 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period.Is New 90 Day High Low • Sep 25New 90-day low: NT$14.15The company is down 28% from its price of NT$19.75 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.株主還元6610TW BiotechsTW 市場7D-6.2%-2.4%-1.4%1Y23.6%88.8%87.5%株主還元を見る業界別リターン: 6610過去 1 年間で88.8 % の収益を上げたTW Biotechs業界を下回りました。リターン対市場: 6610は、過去 1 年間で87.5 % のリターンを上げたTW市場を下回りました。価格変動Is 6610's price volatile compared to industry and market?6610 volatility6610 Average Weekly Movement5.7%Biotechs Industry Average Movement6.0%Market Average Movement6.4%10% most volatile stocks in TW Market11.8%10% least volatile stocks in TW Market2.7%安定した株価: 6610 、 TW市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 6610の 週次ボラティリティ は、過去 1 年間で14%から6%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201027Chen-En Tsaiwww.twibiotech.comTWi Biotechnology, Inc.は臨床段階のバイオ医薬品会社で、台湾で自然免疫関連疾患の治療薬の開発・販売を行っている。同社の開発パイプラインは、単純性表皮水疱症、表皮水疱症、関節炎、痛風、糖尿病を含む様々な適応症で臨床第2相試験中のAC-203と、白斑の治療薬として臨床第1相試験中であり、アトピー性皮膚炎、環状肉芽腫、稀な自己免疫性皮膚疾患の治療薬として前臨床段階にあるAC-1101で構成されている。中国本土、香港、マカオ市場では香港ウィンヘルス製薬グループと医薬品開発契約を結んでいる。TWi Biotechnology, Inc.は2010年に設立され、台湾の台北を拠点としている。もっと見るTWi Biotechnology, Inc. 基礎のまとめTWi Biotechnology の収益と売上を時価総額と比較するとどうか。6610 基礎統計学時価総額NT$5.59b収益（TTM）-NT$299.40m売上高(TTM)n/a0.0xP/Sレシオ-18.7xPER（株価収益率6610 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計6610 損益計算書（TTM）収益NT$0売上原価NT$0売上総利益NT$0その他の費用NT$299.40m収益-NT$299.40m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-1.46グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%6610 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/24 19:45終値2026/08/24 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TWi Biotechnology, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Yu-Ying YangKGI Securities Co. Ltd.
New Risk • Jun 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 132% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$293m free cash flow). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (132% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
お知らせ • Mar 23TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026, at 09:00 Taipei Standard Time. Location: no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$2.27b market cap, or US$72.4m).
New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$1.50b (US$48.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$1.50b market cap, or US$48.2m).
New Risk • Sep 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$156m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$156m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$928.9m market cap, or US$31.0m).
New Risk • Jun 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 132% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$293m free cash flow). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (132% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
お知らせ • Mar 23TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026TWi Biotechnology, Inc., Annual General Meeting, Jun 09, 2026, at 09:00 Taipei Standard Time. Location: no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$2.27b market cap, or US$72.4m).
New Risk • Nov 17New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$1.50b (US$48.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (23% increase in shares outstanding). Market cap is less than US$100m (NT$1.50b market cap, or US$48.2m).
New Risk • Sep 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding).
New Risk • May 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$156m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$156m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 21% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (NT$928.9m market cap, or US$31.0m).
New Risk • Apr 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$838.6m market cap, or US$25.4m).
お知らせ • Mar 20TWi Biotechnology, Inc., Annual General Meeting, Jun 06, 2025TWi Biotechnology, Inc., Annual General Meeting, Jun 06, 2025, at 09:00 Taipei Standard Time. Location: no,399, jui kuang rd., neihu district, taipei city Taiwan
New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$190m free cash flow). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.16b market cap, or US$35.4m).
New Risk • Aug 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NT$190m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$190m free cash flow). Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.22b market cap, or US$37.7m).
お知らせ • Mar 29TWi Biotechnology, Inc., Annual General Meeting, Jun 26, 2024TWi Biotechnology, Inc., Annual General Meeting, Jun 26, 2024.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.23b market cap, or US$39.0m).
New Risk • Jan 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.22b market cap, or US$39.0m).
New Risk • Oct 23New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding). Market cap is less than US$100m (NT$1.54b market cap, or US$47.4m).
お知らせ • Jun 03TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)TWi Biotechnology, Inc. announced that it is currently seeking participants for a Phase 1 clinical trial of a topical gel called tofacitinib for the treatment of granuloma annulare (GA). The TWiB team and collaborating physicians invite eligible individuals to participate in this study at Yale University Hospital.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • May 02Full year 2021 earnings released: NT$0.23 loss per share (vs NT$1.51 loss in FY 2020)Full year 2021 results: NT$0.23 loss per share (up from NT$1.51 loss in FY 2020). Revenue: NT$66.4m (up NT$65.2m from FY 2020). Net loss: NT$15.3m (loss narrowed 85% from FY 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 20TWi Biotechnology, Inc., Annual General Meeting, Jun 07, 2021TWi Biotechnology, Inc., Annual General Meeting, Jun 07, 2021.
Is New 90 Day High Low • Mar 11New 90-day high: NT$19.00The company is up 23% from its price of NT$15.50 on 11 December 2020. The Taiwanese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period.
お知らせ • Jan 08Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases. The prevalence of EB in the United States is about 10.65 per million, equivalent to an estimated 15,000 patients in China. Hereditary epidermolysis bullosa (EB) is a group of rare hereditary skin diseases. Due to genetic mutations, the skin becomes very fragile, just like the wings of a butterfly. A slight collision or friction produces blisters or bloody vesicles, which may then cause trauma and ulceration. Other mucosal tissues of the body may also be affected. There is no effective treatment for EB worldwide. EB is listed in the first national list of 121 rare diseases in China. Based on clinical studies conducted, AC-203 alleviates EB symptoms, reducing blister formation and accelerating wound healing, while also demonstrating a good safety profile. AC-203 has been granted Orphan Drug Designation and rare pediatric drug status by FDA.
分析記事 • Dec 29We're Hopeful That TWi Biotechnology (GTSM:6610) Will Use Its Cash WiselyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Is New 90 Day High Low • Nov 27New 90-day high: NT$17.15The company is up 5.0% from its price of NT$16.40 on 28 August 2020. The Taiwanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Oct 13New 90-day low: NT$13.85The company is down 41% from its price of NT$23.40 on 15 July 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 16% over the same period.
Is New 90 Day High Low • Sep 25New 90-day low: NT$14.15The company is down 28% from its price of NT$19.75 on 24 June 2020. The Taiwanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
